

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

Market Report | 2025-01-28 | 578 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The point of care diagnostics market is estimated to reach USD 22.63 billion in 2029 from the forecasted value of USD 15.05 billion in 2024 at a CAGR of 8.5%. One of the primary reasons that will fuel POC testing is the favourable government initiatives and funding. Globally, governments consider these technologies essential in improving the accessibility of health care, bringing down costs, and enhancing outcomes for patients. Many governments also provide financial support in addition to the provision of grants with regulatory incentives to focus on the development and adoption of POC testing solutions. In developing countries with a lack of proper health care facilities, the governments encourage using POC devices abundantly, decentralizing tests for more underserved populations. Such supportive measures accelerate the adoption of POC diagnostics and thus are opening new market opportunities for diagnostic companies.

"Infectious disease testing products segment is expected to have the fastest growth rate in the point of care diagnostics market, by product, during the forecast period."

The point of care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products, based on product. Infectious disease testing products are expected to witness the fastest growth in the point of care diagnostics market, mainly driven by the high prevalence of infectious diseases worldwide. The increased demand for fast, accurate, and decentralized healthcare diagnostic solutions for community clinics and rural health centers has been driving the demand in this segment.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Improved technologies that include faster molecular diagnostics and enhanced immunoassay platforms enhance the speed and efficiency of accuracy in POC testing. Moreover, with an increase in public health initiatives and growing awareness of the POC solutions for infectious diseases, adoption of these products is increasing significantly.

"Blood samples segment accounted for the largest market share in the point of care diagnostics market, by sample, during the forecast period."

Based on sample, the point of care diagnostics market is bifurcated into blood samples, urine samples, nasal and oropharyngeal swabs, and other samples. The largest market share is held by blood samples in the point of care diagnostics market. Their critical role lies in detecting the broad spectrum of conditions such as diabetes, cardiovascular diseases, infectious diseases, and metabolic disorders. Blood-based tests are considered accurate, reliable, and offer have high turnaround times for results. Because of this reason, these are the most opted sample type for both clinical and near-patient environments. Also, efficiency in blood-based POC devices has been enhanced by the technological advancements which result in accurate results with minimum sample volumes. Additionally, chronic and infectious diseases continue to be on rise, which is accompanied by a high demand for rapid and convenient diagnostic solutions requiring blood-based tests, which has helped maintain the dominance of blood samples in this market.

"Asia Pacific: The fastest-growing market for point of care diagnostics"

The worldwide market for point of care diagnostics is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the point of care diagnostics market due to several factors. Government efforts to promote early disease detection, prevention, and regular health check-ups is a key driver, with a number of initiatives that encourage widespread health screening and timely intervention. These efforts, coupled with the rising healthcare expenditure across the region, have increased the accessibility and demand for diagnostic solutions. The increasing numbers of chronic conditions, such as diabetes in countries such as India and China have also increased the demand for fast and accurate diagnostic equipment. Improving public health results by early diagnosis and management is enabling more healthcare systems to become involved in adopting POC diagnostics in this region.

The break-up of the profile of primary participants in the point of care diagnostics market:

-□By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

-□By Designation: C-level - 27%, D-level - 18%, and Others - 55%

-□By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Other- 4%

The key players in this market are Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Danaher (US), QuidelOrtho Corporation (US), BD (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), BIOSYNEX SA (France), EKF Diagnostics Holdings plc (UK), Trinity Biotech (Ireland), Werfen (US), Nova Biomedical (US), SEKISUI Diagnostics (US), Boditech Med Inc. (South Korea), Grifols, S.A. (Spain), LifeScan IP Holdings, LLC (US), PTS Diagnostics (US), Eurolyser Diagnostica GmbH (Austria), Response Biomedical (Canada), Alfa Scientific Designs, Inc. (US), BTNX Inc. (Canada), Ascensia Diabetes Care Holdings AG (Switzerland), Fluxergy (US), Precision Biosensor, Inc. (South Korea), ACON Laboratories, Inc. (US), Menarini Diagnostics s.r.l (Italy), OraSure Technologies, Inc. (US), and Mankind Pharma (India) .

Research Coverage:

This research report categorizes the point of care diagnostics market by product (glucose monitoring products, cardiometabolic monitoring products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, tumor/cancer marker testing products, urinalysis testing products, cholesterol testing products, hematology testing products, drugs-of-abuse testing products, thyroid stimulating hormone testing products, fecal occult testing products, and other products), by mode of purchase (OTC testing products and prescription-based testing products), by technology (immunoassays, molecular diagnostics, and biochemistry), by sample (blood samples, urine samples, nasal & oropharyngeal swabs, and other samples), by end user (clinical laboratories, ambulatory care facilities and physician offices, hospitals, critical care centers, and urgent care centers; home care settings and self-testing, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the point of care diagnostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

acquisitions, and agreements. New product & service launches, and recent developments associated with the point of care diagnostics market. Competitive analysis of upcoming startups in the point of care diagnostics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall point of care diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (Growing incidence of infectious disease, increasing prevalence of chronic diseases, favourable government initiatives for point of care testing, and rising number of waived tests), opportunities (Increasing growth potential in emerging markets, rising inclination toward decentralized healthcare system, booming healthcare spending worldwide), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Inadequate standardization with centralized lab methods and premium pricing of novel platforms) influencing the growth of the point of care diagnostics market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the point of care diagnostics market.
- Market Development: Comprehensive information about lucrative markets - the report analyses the point of care diagnostics market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the point of care diagnostics market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), QuidelOrtho Corporation (US), and Danaher (US).

Table of Contents:

1□INTRODUCTION□	49
1.1□STUDY OBJECTIVES□	49
1.2□MARKET DEFINITION□	49
1.3□STUDY SCOPE□	50
1.3.1□MARKET SEGMENTATION AND REGIONS COVERED□	50
1.3.2□INCLUSIONS AND EXCLUSIONS□	51
1.3.3□YEARS CONSIDERED□	52
1.4□CURRENCY CONSIDERED□	53
1.5□STAKEHOLDERS□	53
1.6□SUMMARY OF CHANGES□	53
2□RESEARCH METHODOLOGY□	55
2.1□RESEARCH DATA□	55
2.2□RESEARCH APPROACH□	56
2.2.1□SECONDARY DATA□	56
2.2.1.1□Key secondary sources□	56
2.2.1.2□Key data from secondary sources□	57
2.2.1.3□Objectives□	57
2.2.2□PRIMARY DATA□	58
2.2.2.1□Key primary sources□	58
2.2.2.2□Key data from primary sources□	59

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.2.2.3	Key industry insights	60
2.2.2.4	Breakdown of primary interviews	61
2.3	MARKET SIZE ESTIMATION	61
2.3.1	BOTTOM-UP APPROACH	62
2.3.1.1	Company revenue estimation approach	62
2.3.1.2	Presentations of companies and primary interviews	63
2.3.1.3	Growth forecast	63
2.3.1.4	CAGR projections	63
2.3.2	TOP-DOWN APPROACH	64
2.4	DATA TRIANGULATION	65
2.5	MARKET SHARE ANALYSIS	65
2.6	RESEARCH ASSUMPTIONS	66
2.6.1	PARAMETRIC ASSUMPTIONS	66
2.6.2	GROWTH RATE ASSUMPTIONS	66
2.7	RESEARCH LIMITATIONS	66
2.8	RISK ASSESSMENT	67
?		
3	EXECUTIVE SUMMARY	68
4	PREMIUM INSIGHTS	74
4.1	POINT OF CARE DIAGNOSTICS MARKET OVERVIEW	74
4.2	POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029	75
4.3	POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029	76
4.4	POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029	76
4.5	POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029	77
4.6	POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029	77
4.7	POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	78
5	MARKET OVERVIEW	79
5.1	INTRODUCTION	79
5.2	MARKET DYNAMICS	79
5.2.1	DRIVERS	80
5.2.1.1	Growing incidence of infectious diseases	80
5.2.1.2	Increasing prevalence of chronic diseases	81
5.2.1.3	Favorable government initiatives for point of care testing	83
5.2.1.4	Rising number of waived tests	84
5.2.2	RESTRAINTS	85
5.2.2.1	Pricing pressure on manufacturers	85
5.2.2.2	Stringent regulatory approval process for product commercialization	86
5.2.3	OPPORTUNITIES	86
5.2.3.1	Increasing growth potential in emerging markets	86
5.2.3.2	Rising inclination toward decentralized healthcare system	87
5.2.3.3	Booming healthcare spending worldwide	87
5.2.4	CHALLENGES	88
5.2.4.1	Inadequate standardization with centralized lab methods	88
5.2.4.2	Premium pricing of novel platforms	88
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS	89
5.4	PRICING ANALYSIS	90
5.4.1	AVERAGE SELLING PRICE, BY PRODUCT	90

5.4.2	AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER	91
5.4.3	AVERAGE SELLING PRICE, BY REGION	91
5.4.3.1	Average selling price of glucose monitoring test strips, by region	91
5.4.3.2	Average selling price of infectious disease testing products, by region	92
5.4.3.3	Average selling price of cardiometabolic monitoring products, by region	93
5.5	VALUE CHAIN ANALYSIS	94
5.6	SUPPLY CHAIN ANALYSIS	95
5.7	ECOSYSTEM ANALYSIS	96
5.8	INVESTMENT AND FUNDING SCENARIO	98
5.9	TECHNOLOGY ANALYSIS	99
5.9.1	KEY TECHNOLOGIES	99
5.9.1.1	Immunoassays	99
5.9.2	COMPLEMENTARY TECHNOLOGIES	100
5.9.2.1	Molecular diagnostics	100
5.9.3	ADJACENT TECHNOLOGIES	100
5.9.3.1	Biochemical technologies	100
5.10	PATENT ANALYSIS	101
5.11	TRADE ANALYSIS	103
5.11.1	IMPORT DATA FOR HS CODE 3822	103
5.11.2	EXPORT DATA FOR HS CODE 3822	103
5.12	KEY CONFERENCES AND EVENTS, 2025-2026	104
5.13	PORTER'S FIVE FORCES ANALYSIS	105
5.13.1	BARGAINING POWER OF SUPPLIERS	106
5.13.2	BARGAINING POWER OF BUYERS	106
5.13.3	THREAT OF NEW ENTRANTS	106
5.13.4	THREAT OF SUBSTITUTES	106
5.13.5	INTENSITY OF COMPETITIVE RIVALRY	106
5.14	KEY STAKEHOLDERS AND BUYING CRITERIA	107
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	107
5.14.2	KEY BUYING CRITERIA	108
5.15	IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET	109
5.15.1	INTRODUCTION	109
5.15.2	MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET	109
5.15.3	AI USE CASES	110
5.15.4	KEY COMPANIES IMPLEMENTING AI	111
5.15.5	FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET	112
5.16	REGULATORY LANDSCAPE	112
5.16.1	REGULATORY ANALYSIS	112
5.16.1.1	North America	112
5.16.1.1.1	US	112
5.16.1.1.2	Canada	114
5.16.1.2	Europe	114
5.16.1.2.1	Germany	115
5.16.1.2.2	UK	115
5.16.1.2.3	France	116
5.16.1.2.4	Italy	116
5.16.1.2.5	Spain	116

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.16.1.3	Asia Pacific	117
5.16.1.3.1	China	117
5.16.1.3.2	Japan	117
5.16.1.3.3	India	119
5.16.1.3.4	Australia	119
5.16.1.3.5	South Korea	120
5.16.1.4	Latin America	120
5.16.1.4.1	Brazil	121
5.16.1.4.2	Mexico	121
5.16.1.5	Middle East	122
5.16.1.5.1	Africa	122
5.16.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	122
5.17	CASE STUDY ANALYSIS	124
5.17.1	CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK	124
5.17.2	CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA	125
5.17.3	CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS	125
6	POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT	126
6.1	INTRODUCTION	127
6.2	GLUCOSE MONITORING PRODUCTS	128
6.2.1	GLUCOSE MONITORING STRIPS	131
6.2.1.1	Growing trend toward preventive healthcare to drive market	131
6.2.2	GLUCOSE MONITORING METERS	134
6.2.2.1	Growing technological advancements in glucose meters to propel market	134
6.2.3	GLUCOSE MONITORING LANCETS & LANCING DEVICES	137
6.2.3.1	Increasing tendency for home-based care and self-monitoring to aid growth	137
6.3	CARDIOMETABOLIC MONITORING PRODUCTS	139
6.3.1	CARDIAC MARKER TESTING PRODUCTS	144
6.3.1.1	Growing government support for cardiovascular diseases to drive market	144
6.3.2	BLOOD GAS/ELECTROLYTE TESTING PRODUCTS	146
6.3.2.1	Need to optimize hospital workflow to favor growth	146
6.3.3	HBA1C TESTING PRODUCTS	149
6.3.3.1	Increasing recommendations by government healthcare authorities to boost market	149
6.4	INFECTIOUS DISEASE TESTING PRODUCTS	151
6.4.1	RESPIRATORY INFECTION TESTING PRODUCTS	154
6.4.1.1	Influenza testing products	156
6.4.1.1.1	Need for targeted treatments to expedite growth	156
6.4.1.2	Tuberculosis	159
6.4.1.2.1	Increasing demand for diagnostic products and services to contribute to growth	159
6.4.1.3	Other respiratory infection testing products	162
6.4.2	HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS	165
6.4.2.1	Growing rate of surgical-site infections to boost market	165
6.4.3	TROPICAL DISEASE TESTING PRODUCTS	168
6.4.3.1	Rising incidence of malaria and dengue to support growth	168
6.4.4	SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS	171
6.4.4.1	HIV testing products	174
6.4.4.1.1	Growing availability and awareness of testing products to boost market	174

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

6.4.4.2	Hepatitis testing products	177
6.4.4.2.1	Hepatitis B testing products	180
6.4.4.2.1.1	Increasing prevalence of liver infections to favor growth	180
6.4.4.2.2	Hepatitis C testing products	183
6.4.4.2.2.1	Need to combat hepatitis among high-risk subgroup populations to aid growth	183
6.4.4.3	Syphilis testing products	185
6.4.4.3.1	Need for early and accessible diagnosis to expedite growth	185
6.4.4.4	Human papillomavirus testing products	189
6.4.4.4.1	Rising cases of cervical cancer to promote growth	189
6.4.4.5	Chlamydia trachomatis testing products	192
6.4.4.5.1	Growing adoption of advanced techniques to drive market	192
6.4.4.6	Neisseria gonorrhea testing products	195
6.4.4.6.1	Rising incidence of gonorrhea and antimicrobial resistance to augment growth	195
6.4.4.7	Herpes simplex virus testing products	197
6.4.4.7.1	Increasing incidence of herpes to support growth	197
6.4.5	CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS	200
6.4.5.1	Rising cases among hospitalized patients to boost demand	200
6.4.6	OTHER INFECTIOUS DISEASE TESTING PRODUCTS	202
6.5	COAGULATION MONITORING PRODUCTS	205
6.5.1	PT/INR TESTING PRODUCTS	208
6.5.1.1	Increasing number of atrial fibrillation cases to accelerate growth	208
6.5.2	ACT/APTT TESTING PRODUCTS	210
6.5.2.1	Rise in surgical procedures to speed up growth	210
6.6	PREGNANCY & FERTILITY TESTING PRODUCTS	212
6.6.1	PREGNANCY TESTING PRODUCTS	215
6.6.1.1	Increasing awareness about family planning to stimulate growth	215
6.6.2	FERTILITY TESTING PRODUCTS	218
6.6.2.1	Growing infertility issues to fuel market	218
6.7	TUMOR/CANCER MARKER TESTING PRODUCTS	220
6.7.1	GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET	220
?		
6.8	URINALYSIS TESTING PRODUCTS	224
6.8.1	INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH	224
6.9	CHOLESTEROL TESTING PRODUCTS	227
6.9.1	RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH	227
6.10	HEMATOLOGY TESTING PRODUCTS	230
6.10.1	INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH	230
6.11	DRUGS-OF-ABUSE TESTING PRODUCTS	233
6.11.1	GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET	233
6.12	THYROID-STIMULATING HORMONE TESTING PRODUCTS	236
6.12.1	RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH	236
6.13	FECAL OCCULT TESTING PRODUCTS	239
6.13.1	GROWING INCIDENCE OF CANCER TO PROPEL MARKET	239
6.14	OTHER PRODUCTS	242
7	POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE	246
7.1	INTRODUCTION	247
7.2	PRESCRIPTION-BASED TESTING PRODUCTS	247

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.1	RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH	247
7.3	OTC TESTING PRODUCTS	251
7.3.1	GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET	251
8	POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY	255
8.1	INTRODUCTION	256
8.2	BIOCHEMISTRY	256
8.2.1	INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH	256
8.3	IMMUNOASSAYS	260
8.3.1	GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET	260
8.4	MOLECULAR DIAGNOSTICS	264
8.4.1	RT-PCR	267
8.4.1.1	Growing use of RT-PCR in proteomics and genomics to boost market	267
8.4.2	INAAT	270
8.4.2.1	Emerging new pathogens to facilitate growth	270
9	POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE	273
9.1	INTRODUCTION	274
9.2	BLOOD SAMPLES	274
9.2.1	GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET	274
9.3	NASAL & OROPHARYNGEAL SWABS	278
9.3.1	INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH	278
9.4	URINE SAMPLES	281
9.4.1	NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET	281
9.5	OTHER SAMPLES	285
10	POINT OF CARE DIAGNOSTICS MARKET, BY END USER	289
10.1	INTRODUCTION	290
10.2	HOME CARE SETTINGS AND SELF-TESTING	290
10.2.1	INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH	290
10.3	CLINICAL LABORATORIES	293
10.3.1	GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET	293
10.4	HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS	296
10.4.1	RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH	296
10.5	AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES	299
10.5.1	NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH	299
10.6	OTHER END USERS	301
11	POINT OF CARE DIAGNOSTICS MARKET, BY REGION	305
11.1	INTRODUCTION	306
11.2	NORTH AMERICA	306
11.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	316
11.2.2	US	316
11.2.2.1	Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth	316
11.2.3	CANADA	323
11.2.3.1	Rising incidence of diabetes and infectious diseases to support growth	323
11.3	EUROPE	331
11.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	338
11.3.2	GERMANY	339
11.3.2.1	Increasing need for rapid and accurate diagnostic solutions to promote growth	339
11.3.3	FRANCE	346

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3.3.1	Growing demand for accessible and convenient diagnostic tools to propel market	346
11.3.4	UK	352
11.3.4.1	Rising number of accredited clinical and hospital laboratories to sustain growth	352
11.3.5	ITALY	359
11.3.5.1	Growing burden of infectious and parasitic diseases to boost market	359
	?	
11.3.6	SPAIN	367
11.3.6.1	Rising prevalence of circulatory system diseases to contribute to growth	367
11.3.7	REST OF EUROPE	373
11.4	ASIA PACIFIC	380
11.4.1	MACROECONOMIC OUTLOOK FOR ASIA PACIFIC	388
11.4.2	CHINA	389
11.4.2.1	Increasing impact of diabetes on public health to amplify growth	389
11.4.3	JAPAN	395
11.4.3.1	Booming geriatric population to stimulate growth	395
11.4.4	INDIA	403
11.4.4.1	Increasing cases of chronic heart and kidney diseases to foster growth	403
11.4.5	AUSTRALIA	409
11.4.5.1	Growing research investments for next-gen point of care devices to boost market	409
11.4.6	SOUTH KOREA	416
11.4.6.1	Growing focus on innovative diagnostic products to drive market	416
11.4.7	REST OF ASIA PACIFIC	423
11.5	LATIN AMERICA	430
11.5.1	MACROECONOMIC OUTLOOK FOR LATIN AMERICA	437
11.5.2	BRAZIL	438
11.5.2.1	Increasing public initiatives in healthcare to encourage growth	438
11.5.3	MEXICO	444
11.5.3.1	Need for frequent testing for disease management to expedite growth	444
11.5.4	REST OF LATIN AMERICA	451
11.6	MIDDLE EAST & AFRICA	458
11.6.1	GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET	458
11.6.2	MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA	464
11.7	GCC COUNTRIES	465
11.7.1	BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH	465
11.7.2	MACROECONOMIC OUTLOOK FOR GCC COUNTRIES	471
12	COMPETITIVE LANDSCAPE	473
12.1	INTRODUCTION	473
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	473
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET	474
12.3	REVENUE ANALYSIS, 2021-2023	475
12.4	MARKET SHARE ANALYSIS, 2023	476
12.5	COMPANY VALUATION AND FINANCIAL METRICS	478
	?	
12.6	BRAND/PRODUCT COMPARISON	479
12.6.1	ABBOTT	479
12.6.2	F. HOFFMANN-LA ROCHE LTD.	479
12.6.3	NOVA BIOMEDICAL	480

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	480
12.7.1	STARS	480
12.7.2	EMERGING LEADERS	480
12.7.3	PERVASIVE PLAYERS	480
12.7.4	PARTICIPANTS	480
12.7.5	COMPANY FOOTPRINT, KEY PLAYERS, 2023	482
12.7.5.1	Company footprint	482
12.7.5.2	Region footprint	483
12.7.5.3	Mode of purchase footprint	484
12.7.5.4	Technology footprint	485
12.7.5.5	Sample footprint	486
12.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	487
12.8.1	PROGRESSIVE COMPANIES	487
12.8.2	RESPONSIVE COMPANIES	487
12.8.3	DYNAMIC COMPANIES	487
12.8.4	STARTING BLOCKS	487
12.9	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	489
12.9.1	DETAILED LIST OF KEY STARTUPS/SMES	489
12.9.2	COMPETITIVE BENCHMARKING OF STARTUPS/SMES	489
12.10	COMPETITIVE SCENARIO	490
12.10.1	PRODUCT LAUNCHES AND APPROVALS	490
12.10.2	DEALS	491
13	COMPANY PROFILES	493
13.1	KEY PLAYERS	493
13.1.1	ABBOTT	493
13.1.1.1	Business overview	493
13.1.1.2	Products offered	494
13.1.1.3	Recent developments	497
13.1.1.3.1	Product launches and approvals	497
13.1.1.3.2	Deals	497
13.1.1.4	MnM view	498
13.1.1.4.1	Right to win	498
13.1.1.4.2	Strategic choices	498
13.1.1.4.3	Weaknesses and competitive threats	498
13.1.2	SIEMENS HEALTHINEERS AG	499
13.1.2.1	Business overview	499
13.1.2.2	Products offered	500
13.1.2.3	Recent developments	502
13.1.2.3.1	Product launches and approvals	502
13.1.2.3.2	Deals	502
13.1.2.3.3	Expansions	503
13.1.2.4	MnM view	504
13.1.2.4.1	Right to win	504
13.1.2.4.2	Strategic choices	504
13.1.2.4.3	Weaknesses and competitive threats	504
13.1.3	F. HOFFMANN-LA ROCHE LTD	505

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.3.1	Business overview	505
13.1.3.2	Products offered	506
13.1.3.3	Recent developments	508
13.1.3.3.1	Product launches and approvals	508
13.1.3.3.2	Deals	508
13.1.3.3.3	Expansions	509
13.1.3.4	MnM view	509
13.1.3.4.1	Right to win	509
13.1.3.4.2	Strategic choices	509
13.1.3.4.3	Weaknesses and competitive threats	510
13.1.4	DANAHER	511
13.1.4.1	Business overview	511
13.1.4.2	Products offered	512
13.1.4.3	Recent developments	514
13.1.4.3.1	Deals	514
13.1.4.4	MnM view	514
13.1.4.4.1	Key strengths	514
13.1.4.4.2	Strategic choices	514
13.1.4.4.3	Weaknesses and competitive threats	515
13.1.5	QUIDELORTHO CORPORATION	516
13.1.5.1	Business overview	516
13.1.5.2	Products offered	517
13.1.5.3	Recent developments	519
13.1.5.3.1	Product launches and approvals	519
13.1.5.3.2	Deals	520
13.1.5.3.3	Expansions	521
13.1.5.4	MnM view	521
13.1.5.4.1	Right to win	521
13.1.5.4.2	Strategic choices	521
13.1.5.4.3	Weaknesses and competitive threats	521
13.1.6	BD	522
13.1.6.1	Business overview	522
13.1.6.2	Products offered	523
13.1.6.3	Recent developments	524
13.1.6.3.1	Deals	524
13.1.6.3.2	Expansions	524
13.1.7	THERMO FISHER SCIENTIFIC INC.	525
13.1.7.1	Business overview	525
13.1.7.2	Products offered	526
13.1.7.3	Recent developments	527
13.1.7.3.1	Product launches and approvals	527
13.1.7.3.2	Deals	527
13.1.8	BIOMERIEUX	528
13.1.8.1	Business overview	528
13.1.8.2	Products offered	529
13.1.8.3	Recent developments	530
13.1.8.3.1	Product launches and approvals	530

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.1.8.3.2	Deals	531
13.1.9	BIOSYNEX SA	532
13.1.9.1	Business overview	532
13.1.9.2	Products offered	533
13.1.9.3	Recent developments	535
13.1.9.3.1	Deals	535
13.1.10	EKF DIAGNOSTICS HOLDINGS PLC	536
13.1.10.1	Business overview	536
13.1.10.2	Products offered	537
13.1.10.3	Recent developments	538
13.1.10.3.1	Product launches and approvals	538
13.1.10.3.2	Deals	538
13.1.10.3.3	Expansions	539
13.1.11	TRINITY BIOTECH	540
13.1.11.1	Business overview	540
13.1.11.2	Products offered	541
13.1.11.3	Recent developments	542
13.1.11.3.1	Product launches and approvals	542
13.1.11.3.2	Deals	542
13.1.12	WERFEN	543
13.1.12.1	Business overview	543
13.1.12.2	Products offered	544
13.1.12.3	Recent developments	545
13.1.12.3.1	Product launches and approvals	545
13.1.12.3.2	Deals	545
13.1.13	NOVA BIOMEDICAL	546
13.1.13.1	Business overview	546
13.1.13.2	Products offered	546
13.1.13.3	Recent developments	547
13.1.13.3.1	Product launches and approvals	547
13.1.13.3.2	Expansions	548
13.1.14	SEKISUI DIAGNOSTICS	549
13.1.14.1	Business overview	549
13.1.14.2	Products offered	549
13.1.15	BODITECH MED INC.	551
13.1.15.1	Business overview	551
13.1.15.2	Products offered	551
13.1.15.3	Recent developments	552
13.1.15.3.1	Product launches and approvals	552
13.1.15.3.2	Deals	552
13.1.15.3.3	Expansions	553
13.2	OTHER PLAYERS	554
13.2.1	GRIFOLS, S.A.	554
13.2.2	LIFESCAN IP HOLDINGS, LLC	555
13.2.3	PTS DIAGNOSTICS	556
13.2.4	EUROLYSER DIAGNOSTICA GMBH	557
13.2.5	RESPONSE BIOMEDICAL	558

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

13.2.6	ALFA SCIENTIFIC DESIGNS, INC.	559
13.2.7	BTNX INC.	560
13.2.8	ASCENSIA DIABETES CARE HOLDINGS AG	561
13.2.9	FLUXERGY	562
13.2.10	PRECISION BIOSENSOR, INC.	563
13.2.11	ACON LABORATORIES, INC.	564
13.2.12	MENARINI DIAGNOSTICS S.R.L.	565
13.2.13	ORASURE TECHNOLOGIES, INC.	566
13.2.14	MANKIND PHARMA	567
14	APPENDIX	568
14.1	DISCUSSION GUIDE	568
14.2	KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL	574
14.3	CUSTOMIZATION OPTIONS	576
14.4	RELATED REPORTS	576
14.5	AUTHOR DETAILS	577

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Point of Care Diagnostics Market by Product (Glucose, Infectious Disease (TB, HAI, STD), Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx (RT-PCR, INAAT)), Sample (Blood, Urine), End User (Home Care, Hospitals) - Global Forecast to 2029

Market Report | 2025-01-28 | 578 pages | MarketsandMarkets

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scottis-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

Zip Code*

Country*

Date

Signature